Development of resistance to endocrine therapy remains the main obstacle for curing estrogen receptor alpha (ERα)-positive breast cancer, with 30–50% of the patients that initially respond progressing to incurable disease [1,2]. This evidence concerns the gene ESR1 and breast carcinoma.